Evolving liver disease insights from NAFLD to MASLD

Trends Endocrinol Metab. 2024 Feb 29:S1043-2760(24)00041-9. doi: 10.1016/j.tem.2024.02.012. Online ahead of print.ABSTRACTThe recent renaming of 'non-alcoholic fatty liver disease' (NAFLD) to 'metabolic dysfunction-associated steatotic liver disease' (MASLD) emphasizes metabolic dysfunction in steatotic liver disease and advocates for tailored, comprehensive treatment strategies, driving forward the development of personalized care and innovative therapeutic approaches.PMID:38429162 | DOI:10.1016/j.tem.2024.02.012
Source: Trends in Endocrinology and Metabolism: TEM - Category: Endocrinology Authors: Source Type: research